Abstract Over one hundred diseases related to inherited defects of complex lipids synthesis and remodeling are now reported. Most of them were described within the last 5 years.
Introduction
The quantitative importance of lipids in the nervous system makes the brain and peripheral nerves a privileged target for defects of complex lipids synthesis and remodeling. However, besides the role of complex lipids in neurological functions and signaling, this review highlighs the importance of these molecules in photoreceptor function, the epidermal water barrier, bone, and liver metabolism. This chapter is an attempt to give a clinical overview of this new group of IEM focusing on neurological, muscular, cardiac, ophthalmological, dermatological, orthopedic, and hepatic presentations.
Neurological presentations
Both central (CNS) and peripheral nervous systems are frequently involved in complex lipid synthesis and remodeling disorders. Careful grouping of patients in well-defined neurological syndromes is a practical and useful approach for clinicians (Tables 1 and 2 ). However, due to the rapidly growing number of diseases and the expanding phenotype of many of these diseases, this approach needs a constant update. As general messages, we wish to highlight the following points:
-Complex lipid synthesis and remodeling disorders produce prominent motor manifestations due to upper and/or lower motoneuron degeneration. In fact, these movement disorders are the most remarkable neurological presentations in this category of diseases. Motor signs are often complex, associated with other neurological and extraneurological signs. -These disorders should be considered in patients with cerebral-palsy like phenotype, spastic paraparesis, ataxia, NBIA (neurodegeneration associated with brain iron accumulation), and peripheral neuropathy of unknown origin. -In general, psychiatric disturbances are rare. They have been described in different NBIA, especially as late-onset manifestations, but they rarely appear in other types of complex lipid biosynthesis disorders. -Epilepsy is also rare as a prominent sign; however, there are some defects that produce early severe refractory epilepsy.
-Developmental delay (DD) and intellectual disability (ID) are commonly present, as in many other neurometabolic diseases, but in general associated with other neurological and extra-neurological signs as "syndromic mental retardation". These additional signs are often useful to the diagnostic approach. Additionally, one interesting message learnt from these IEM is the inclusion of serum alkaline phosphatase in the metabolic work-up of mental retardation for the detection of GPI-anchor-synthesis defects (Krawitz et al 2013) . Three neurological phenotypes, spastic paraparesis, NBIA, and peripheral neuropathies, deserve especial attention (Tables 1 and 2 ).
Hereditary spastic paraparesis (HSP) - Table 1 HSP is a heterogeneous group of genetic disorders in which the main feature is progressive spasticity in the lower limbs due to pyramidal tract dysfunction as a result of a 'dying back' degeneration of the cortico-spinal tracts. The critical role of complex lipids in signal transduction and membrane rigidity/ fluidity may partly explain how defects in synthesis and remodeling of these lipids often lead to the degeneration of some of the longest, and therefore most vulnerable, axons in the CNS. HSP refers to a syndrome that includes lower extremity weakness and spasticity, each of varying degree, age of onset, and progression. There are more than 50 genetic types of HSP, many of them described in the last years (Lo Giudice et al 2014) . They are classified clinically as "pure" or "uncomplicated" and "complex" or "complicated" (Harding 1983) . While some genetic types of HSP usually manifest as "uncomplicated" -e.g., SPG4 HSP due to spastin gene mutation, the single most common form of autosomal dominant HSP -other genetic types usually present as complex HSP syndromes (Fink 2013) . In general, HSP due to complex lipid biosynthesis defects are autosomal recessive and complicated forms of HSP. Cerebellar involvement, axonal neuropathy, ichthyosis, and ocular abnormalities are amongst the most commonly associated symptoms, together with abnormal brain MRI, especially thin corpus callosum. Rather "pure" HSP, although not invariably, can be observed in SPG28 due to phospholipase A1 deficiency and mutations in DDHD1 (Bouslam et al 2005 ) (Liguori et al 2014) as well as SPG56 due to cytochrome P450 hydroxylase deficiency and mutations in CYP2U1 (Tesson et al 2012) . About 13 different genes associated with HSP and defects in lipid biosynthesis and remodeling have been described up till now. They participate in different biological functions, especially phospholipid remodelling (PNPLA6, CYP2U1, DDHD1 and DDHD2), fatty acid hydroxylation (CYP2U1) as well as sphingolipids biosynthesis (FA2H, B4GALNT1). Neurodegeneration with brain iron accumulation (NBIA) - Table 1 NBIA syndromes represent a group of degenerative extrapyramidal monogenic disorders with accumulation of iron in the brain, usually in the basal banglia (Gregory and Hayflick 2011). In general, NBIA cause progressive dystonia, bulbar symptoms, and pyramidal signs in young children whereas parkinsonism usually appears later. Cognitive decline occurs in some subtypes of NBIA, but more often cognition is relatively spared. Cerebellar atrophy is a frequent finding. So far, ten different genetic forms have been described (Levi and Finazzi 2014) . Two forms are linked to mutations in genes directly involved in iron metabolism: neuroferritinopathy (FTL gene) and aceruloplasminemia -where the ceruloplasmin gene product is defective. In the other forms, the link with iron metabolism is not evident. The biochemical pathways involving lipid metabolism and membrane/ organelles (mitochondria) remodeling seem to play an important mechanistic role in NBIA disorders. At least four genes, PANK2, PLA2G6, COASY, and FA2H, encode proteins involved in lipid metabolism. The protein encoded by c19orf12 is linked to the mitochondrial outer membrane and is presumably connected with lipid metabolism although it has not been completely characterized yet (Hartig et al 2011) .
(Tiranti this issue)
Peripheral neuropathies - Table 2 The diagnosis of peripheral neuropathies, rely on clinical and electrophysiological criteria. The general classification depends on whether there is an involvement of large fibersi.e. motor weakness, loss of deep reflexes, muscle atrophy, sensory ataxia -versus small fibers -autonomic dysfunction, abnormal temperature sensibility pinprick loss -and whether the neuropathy is predominantly demyelinating or axonal. The lipid composition of myelin and transport of lipid-associated myelin proteins contribute to the observed vulnerability of myelin in lipid metabolism disorders (Chrast et al 2011) . Currently, more than 20 genes have been linked to IEM of lipid biosynthesis and remodeling defects. Different subtypes of peripheral neuropathies have been described in these disorders. Most of them are associated with other neurological and extra-neurological signs such as spastic paraparesis, white matter abnormalities, ocular and hearing impairment. However, peripheral neuropathy may be the presenting and/or predominant symptom in some of these diseases. Likewise, diseases of complex lipids biosynthesis and remodeling may present with:
-sensory and autonomic neuropathies, especially defects in serine metabolism either with an early onset -then associated with a global encephalopathy -or with an onset during adolescence to adulthood -with a less severe phenotype (Rotthier et al 2010; Murphy et al 2013; Suh et al 2013 Suh et al , 2014 ). -Demyelinating neuropathies, mainly found in peroxisomal defects such as biogenesis defects related to PEX genes, adrenomyeloneuropathy, X-linked adrenoleukodystrophy and Refsum disease -although peroxisomal diseases can also manifest with axonal neuropathies -Axonal neuropathies, often associated with HSP and usually sharing common pathological pathways with HSP.
Muscular and cardiac symptoms - Table 3 Complex lipid synthesis and remodeling disorders may present with the following skeletal and cardiac muscle predominant manifestations:
-Recurrent rhabdomyolysis with myoglobinuria and myalgia. This is a well-recognized presentation of beta-oxidation defects such as LCHAD and TFP deficiencies (Olpin et al 2005) , as well as Lipin-1 deficiency (Michot et al 2010) . These episodes are frequently triggered by catabolic or other stressful situations. A rare peroxisomal defect, racemase deficiency, has been reported as a cause of recurrent rhabdomyolysis in adults (Kapina et al 2010). -Childhood myopathy mimicking congenital dystrophy, with or without heart involvement. Isolated muscle forms include a severe myopathic phenotype at birth due to 3-hydroxyacyl-CoA dehydratase 1 (PTPLA) deficiency (Muhammad et al 2013) and the Chanarin-Dorfman syndrome (alpha/beta hydrolase 5 (ABHD5) deficiency). Myopathies with variable cardiac involvement encompass (i) an early onset form with mental retardation and abnormal mitochondrial morphology -i.e., choline kinase beta (CHKB) deficiency (Mitsuhashi et al 2011) , (ii) severe early encephalopathies with seizures and associated signs -i.e., defects in dolichol metabolism (Lefeber et al 2011; Barone et al 2012) ; (iii) Sengers syndrome; a n d ( i v ) a n a d u l t o n s e t m y o p a t h y a n d cardiomyovasculopathy -i.e., neutral lipid storage disease or triglyceride deposit (PNPLA2) (Kaneko et al 2014). -Primary or prominent cardiac presentations revealed by dilated or hypertrophic cardiomyopathy, such as DK1 mutations (Kapusta et al 2012), Barth syndrome (Clarke et al 2013) , and Sengers syndrome (Mayr et al 2012) . Ophthalmological presentations - Retinal dystrophies -retinitis pigmentosa, Leber congenital amaurosis, early onset retinal dystrophy and Stargardt disease
There are over four hundred known inherited diseases in which the retina, macula or choroids are substantially involved (Rattner et al 1999; Retnet) . Retinitis pigmentosa (RP) is the name commonly given to a group of diseases with degeneration of the retina leading to a progressive visual field loss, night blindness, and abnormal or non recordable electroretinogram. In typical RP, rod photoreceptors are affected more severely than cones early in the disease. A deficiency in dim light is often the first visual symptom and is due to the degeneration or malfunctioning of rods throughout the retina. Diffuse loss of both rod and cone sensitivity leads to blindness. Biochemical studies have revealed that the pathophysiology related to the degeneration of the photoreceptor cells of the retina can be divided into three large groups: (i) a primary biochemical defect inherent to the photoreceptor cells; (ii) a primary biochemical defect in neighboring retinal cells such as the retinal pigment epithelium (RPE) -a CNS derivative that separates the retina from the choroidal circulation; and (iii) a peculiar sensitivity of the photoreceptors or the retinal pigment epithelium to a generalized metabolic defect (Drijja 2001). In secondary RP, the retinal degeneration is associated with other systemic abnormalities, including neurological dysfunction, hearing loss, dysmorphism, skin abnormalities, nephropathy, and myopathy. Although the basic pathophysiology of RP is not known, the occurrence of RP in metabolic disorders suggests that it might be induced by abnormal metabolic products, errors of synthetic pathways or deficient energy metabolism (Poll-The et al 1992; . The lipid phase of the photoreceptor outer segment membrane is essential to the photon capturing and signaling functions of rhodopsin. The rearrangement of phospholipids in the bilayer accompanies the formation of the active intermediates of rhodopsin following photon absorption. ABCA4 is implicated in the transport of a retinal phospholipid compound across membranes of the photoreceptor outer segment disc. All-trans retinal released from rhodopsin is reduced to all-trans retinol and subsequently shuttled to the RPE cells where it is sequentially converted back to 11-cis retinal for the regeneration of rhodopsin (Molday et al 2009) . These last steps involve consecutively lecithin:retinol acyl transferase (LRAT) and RPE 65 isomerase. All these steps have been found implicated in various forms of RP and Leber congenital amaurosis (LCA) (Mackay et al 2013) . LCA is a severe retinal dystrophy with infantile onset that presents with profound visual impairment, inability to fixate, and nystagmus from birth or within the first few weeks of life. It is the most severe form among the spectrum of these disorders arising within the first few years of life and affecting both rod and cone photoreceptors, also called childhood or early onset retinal dystrophy (EORD) (Gu et al 1997) . The term juvenile RP has also been used to describe EORD. Autosomal recessive RP falls into this spectrum of disorders with onset typically later in childhood or beyond. Depending on the age at diagnosis, the retinal appearance may be normal or there may be a variety of abnormalities including vascular narrowing, macular atrophy, peripheral white dots at the level of the RPE, and retinal pigmentation. The full-field electroretinogram (ERG) is usually non-detectable with conventional ERG testing or severely decreased before the age of 1 year. LCA, EORD, and RP may be considered as a continuum spectrum of retinal dystrophies, in which LCA represents the most severe form due to its age of onset and functional outcome.
Stargardt disease is the most common autosomal recessive, early onset macular dystrophy. Affected individuals display significant loss in central vision with a marked reduction in visual acuity in their first or second decade of life. Progressive decrease in visual acuity generally occurs throughout life with values reaching 20/200 or worse in the final stages of the disease. Stargardt patients also show a delay in dark adaptation and variable loss in color vision. Ophthalmoscopic examination of Stargardt patients typically reveals bilateral atrophic changes in the macula associated with the degeneration of photoreceptor cells and the underlying RPE. Two genes associated with inherited macular degenerative diseases encode proteins whose function is to process lipids in photoreceptor cells: ABCA4 mutations cause the autosomal recessive Stargardt macular degeneration and ELOVL4 mutations lead to the autosomal dominant Stargardt-like disease (Molday and Zhang 2010) . In addition to Stargardt disease, mutations in ABCA4 are known to result in two more severe, but clinically distinct, retinal degenerative diseases: a cone-rod dystrophy and the autosomal recessive retinitis pigmentosa 19. Cone-rod dystrophy (CRD) is a retinal disorder in which cone photoreceptor cells degenerate before rod cells. Mutations in ABCA4 account for 30-60 % of autosomal recessive CRD. In some cases, Stargardt disease can evolve into a CRD. Likewise, it is now generally believed that mutations in ABCA4 result in a spectrum of related retinal dystrophies, the severity of which depends on the type of mutations, its effect on protein function, age of onset, and genetic modifiers (Molday et al 2009) .
Optic nerve degeneration -optic atrophy and glaucoma Hereditary optic atrophy (OA) is common in neurodegenerative diseases due to IEM, especially white matter diseases and energy deficiencies, and deserves an extensive work-up (Saudubray 2012) . The OA and cortical blindness that occur early in the course of Krabbe disease -globoid cell leukodystrophy, galactosylceramid lipidosis -are a direct consequence of the severe loss of myelin and oligodendroglia that is characteristic of this disorder. Although the OA develops early in the disease course, it is usually overshadowed by the neurological deterioration. OA is also frequent in metachromatic leukodystrophy and may result in severely impaired vision. OA is a frequent early presenting sign of primaryLeber hereditary optic neuropathy, respiratory chain deficiencies, pyruvate dehydrogenase deficiency, biotinidase deficiency, Costeff optic atrophy syndrome -or secondary -organic acidurias -mitochondrial dysfunction. By contrast, OA appears to be a rather rare ocular finding in disorders of complex lipids synthesis compared to retinal dystrophies. Nonetheless, visual loss and OA are early presenting sign in several disorders of dolichol synthesis and remodeling pathway (Lefeber this issue). It is also a very frequent and early significant sign in some NBIA -INAD and MPAN -in which an impairment of mitochondrial function is strongly suspected in disease development and/or progression. In this respect, it is relevant that the mitochondria-associated membrane of the endoplasmic reticulum is a major site of phospholipid biosynthesis and trafficking (Tiranti this issue).
Glaucoma is characterized by the progressive loss of visual fields due to the degeneration of the optic nerve, usually associated with increased intraocular pressure. Early onset glaucoma is a major diagnostic sign in Charcot-Marie-Tooth disease type 4B2, due to mutations in the gene SBF2 that is involved in phosphoinositide metabolism.
Dermatological presentations -Table S2
About 30 inherited disorders of complex lipids synthesis, remodeling, catabolism, and transport presenting with ichthyosis have been described so far. According to the most recent ichthyosis consensus conference (Oji et al 2010) , inherited ichthyoses belong to a large and heterogeneous group of mendelian disorders of cornification and involve the entire integument. This classification remains clinically based and distinguishes between syndromic and non syndromic ichthyosis forms. Bullous ichthyosis/epidermolytic hyperkeratosis was redefined as keratinopathic ichthyosis. Autosomal recessive congenital ichthyosis (ARCI) refers to harlequin ichthyosis, lamellar ichthyosis, and congenital ichthyosiform erythroderma. At least six inherited lipids synthesis disorders are responsible for non syndromic ARCI, all but one -linked to epidermal lipase N deficiency -presenting at birth with a collodion baby aspect. The vast majority of ichthyosis linked to complex lipids disorders present as neuro-cutaneous syndromes, chondrodysplasia punctata or multiple congenital anomalies -CDG syndromes, neuro laxova syndrome. Among the neuro-cutaneous syndromes comprising spastic paraparesis, Sjögren-Larsson syndrome -ALDH deficiency -presents at birth with a very severe pruriginous ichthyosis that responds dramatically to Zileuton (Willemsen et al 2001) . Sterol methyl-C4 oxidase, a sterol metabolism disorder, is another treatable ichthyosis with a spectacular improvement on statin and cholesterol supplement (He et al 2011) .
Erythrokeratodermia variabilis (EKV), which is characterized by migratory erythematous patches and more fixed, symmetric hyperkeratotic plaques often with palmo-plantar involvement, is genetically heterogeneous; in 50 to 65 % of cases, it can be caused by mutations in GJB3 coding for a gap junction protein connexin. Previously, erythrokeratodermia was differentiated from the ichthyosis group as, in most cases, it is not generalized. However, the majority of the participants to the consensus conference thought that the inclusion of EKV into the ichthyosis classification is appropriate. Interestingly, an early EKV associated with autosomal dominant late onset spinocerebellar ataxia has been recently shown to be caused by ELOVL4 heterozygote mutation (Cadieux-Dion et al 2014) .
Another intriguing skin manifestation of complex lipids metabolism disorders is the inflammatory dermatosis -i.e., Sweet syndrome -observed in Majeed syndrome due to lipin 2 deficiency (Ferguson et al 2005) , which highlights the potential role of complex lipids in inflammation (Csaki et al 2013) .
Orthopedic presentations - Table 4 Over 20 inborn errors affecting the synthesis or remodeling of phosphatidylcholine, phosphatidylserine, phosphatidylinositol, plasmalogens or cholesterol present with major bone and cartilage involvement. Schematically, three clinical entities may be recognized: congenital bone dysplasia, overgrowth disorders, and inflammatory presentations.
Congenital bone dysplasia
Besides rhizomelic chondrodysplasia punctate (Brites this issue) and the already well-known defects of cholesterol and plasmalogen biosynthesis responsible for a variety of bone dysplasia and polymalformative syndromes (Waterham and Ebberink 2012) , several original entities affecting phospholipids metabolism have been recently described. They involve mostly the synthesis, transport or activating pathways of phosphoserine (Wortmann et al 2014) and phosphatidyl inositides (Balla 2013) : (i) Lenz-Majewski syndrome, a sclerosing bone dysplasia is caused by a gain of function mutation in the gene encoding phosphatidylserine synthase 1 (PTDSS1), which impairs the negative feedback regulation of the enzyme by its reaction product phosphoserine (Sousa et al 2014, Wortmann this 
Segmental overgrowth disorders with congenital lipomatosis
The molecular etiology of somatic overgrowth syndromes has been recently clarified and allowed the clinical delineation and natural history of the PIK3CA-related overgrowth spectrum (Keppler-Noreuil et al 2014; Lindhurst et al 2012) . The spectrum of diseases associated with PIK3CA mutations include fibroadipose overgrowth, hemihyperplasia multiple lipomatosis, congenital lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis/skeletal and spinal syndrome (CLOVES), macrodactyly, and the megalencephaly-capillary malformation syndrome (MCAP). It appears that all these phenotypes have a considerable overlap and are associated with somatic gain of functions of phosphoinositol kinase 3 resulting in an overactivation of the phosphatidylinositol/AKT/mTOR pathway. PIK3CA mutations are detected in affected tissues or cultured cells at varying levels, but not in the blood or saliva. There is not a clear correlation between the mutation level in either tissues or cultured cells to either the type or the severity of the manifestations. Apart from the class IA of PI3Ks, human diseases are rarely caused by activating mutations of inositide lipid kinases. Moreover, loss of function of inositol lipid kinases is rarely seen in human diseases. The only report on an inactivating mutation Gaucher disease type 1 (AR) Bone involvement is an important concern in late childhood to adulthood. Medullary infarction of long bones may cause excruciating pain ("bone crisis"). Aseptic necrosis of femoral head and spontaneous fractures due to osteopenia are common findings and can be inaugural.
Glucocerebrosidase type 1
GBA Vanier and Caillaud 2012
Phosphocholine Citidylyl transferase deficiency (AR)
Spondylometaphyseal dysplasia (short stature with rhizomelia, platyspondyly, metaphyseal irregularity, bowing of long bones) with cone-rod dystrophy.
Phosphocholine citidylyl transferase (alpha isoform)
PCYT1A Wortmann this issue
Lenz Majewski hyperostotic dwarfism syndrome (AD) Progressive generalized hyperostosis leading to severe growth restriction, typical craniofacial dysmorphic features (thickness of the jaw, clavicles and ribs), distal-limb abnormalities (proximal symphalangism), cutis laxa, intellectual disability.
Phosphatidylserine synthase 1 gain-of-function of the PIP 5-kinase I gene was associated with severe developmental abnormalities with perinatal lethality (Narkis et al 2007) .
Conversely, an increasing number of rare human diseases such as Joubert syndrome, Lowe syndrome, Charcot-Marie-Tooth disease type 4B1 or X-linked myotubular myopathy are linked to phosphoinositide phosphatase defects and cause very specific phenotypes (Balla 2013) .
Inflammatory presentations
Recurrent aseptic necrosis and medullary infarction of long bones in an inflammatory context are a frequent diagnostic finding in Majeed syndrome and Gaucher disease. These symptoms represent a major clinical concern.
Hepatic presentations - Table S3 Complex lipids synthesis and remodeling disorders may be associated with three preponderant hepatic presentations.
The first presentation is a transient neonatal to early infantile cholestatic jaundice and/or liver failure followed by a neurodegenerative disorder. Beside the well-known Niemann-Pick type C disease (Vanier 2010) , cholestatic jaundice may be the first manifestation of several diseases affecting the synthesis of cholesterol and bile acids. In most cases, the jaundice spontaneously resolves but psychomotor delay, peripheral neuropathy and/or motor dysfunction develop during the first decade or even later. In the so-called infantile Refsum disease -a peroxisome biogenesis defect -the neonatal jaundice is commonly followed by a 1 to 3 years phase of failure to thrive with hepatomegaly, osteoporosis, and hypocholesterolemia before neurologic symptoms, RP, and deafness arise. Megdel syndrome also presents first with recurrent episodes of liver failure, similar to what is seen in mitochondrial DNA depletion syndromes, before the onset of dystonia and a Leigh-like encephalopathy (Sarig et al 2013; Wortmann this issue) .
Major hepatosplenomegaly is another preponderant diagnostic sign, evocative of many lysosomal disorders involving the catabolism and recycling of complex sphingolipids. Mevalonate kinase deficiency presents early in life with acute recurrent inflammatory crisis, fever, skin rashes, arthralgia, hepatosplenomegaly, and severe recurrent anemia (Houten et al 2003) .
Finally, non-alcoholic liver steatosis is a presenting sign in several IEM involving triglyceride biosynthesis. Indeed, the liver is a central organ in the regulation of triglycerides metabolism; it participates in triglyceride synthesis, export, uptake and oxidation. Hepatocytes can shift from intensive fatty acid synthesis -in fed state -to rapid fatty acid breakdown -during (Bielas et al 2009); Renal cysts are a cardinal sign in the hepato-cerebrorenal Zellweger syndrome resulting from peroxisome biogenesis defects. Disorders of complex lipids biosynthesis may also involve the immune system: (i) PIK3CD mutations cause a combined immune deficiency; (ii),PIK3R1 mutations are responsible for an autosomal recessive agammaglobulinemia; and (iii) the recently described deletions of PLCG2, which encodes phospholipase Cγ(2) -an enzyme expressed in B cells, natural killer cells, and mast cells -present with cold urticaria, immunodeficiency, and autoimmunity (Ombrello et al 2012) .
Conclusion
This review attempts to give a clinical overview of disorders affecting the synthesis and remodeling of phospholipids and other complex lipids. Many metabolic and genetic factors may account for the clinical diversity of these disorders. The quantitative importance of lipids in the nervous system makes the brain and peripheral nerves a privileged target for these lipids synthetic defects. Mitochondrial membranes that are very rich in cardiolipin and phosphoethanolamine should be particularly vulnerable to mutations affecting these molecules. The tissue specificity of some complex lipid molecules also probably accounts for some specific clinical presentations. Hence the high concentration of cardiolipin in muscle and its very small content in the brain may underlie the predominant muscle/cardiac presentation of Barth syndrome with no or minimal involvement of the nervous system. Similarly, the confinement to skeletal muscles of clinical manifestations of Lipin-1 mutations might be related to the nearly ubiquitous expression of the two other LPIN genes (LPIN2 and LPIN3). The constant CNS involvement observed in phospholipase A2 deficiency is probably related to the major and predominant expression of this enzyme in the brain even if the clinical heterogeneity is still poorly understood. It is noteworthy that identical mutations affecting the same enzyme can give rise to very different phenotypes like in ELOVL4 mutations which may present as an autosomal dominant spinocerebellar ataxia with erythrokeratodermia (Cadieux-Dion et al 2014), a dominant form of Stargardt disease type 3 or a recessive neuroichthyotic syndrome resembling a severe presentation of Sjögren-Larsson disease. Another example of such an intriguing phenotypic heterogeneity are mutations in PCYT1A, encoding choline-phosphate cytidylyltransferase A, which may present as a spondylometaphyseal dysplasia with cone rod dysfunction or as a congenital lipodystrophy with fatty liver disease but any bone or retina involvement . Tissue specificity might also be responsible for many non syndromic phenotypes, like (i) immune deficiencies syndromes related to mutations in genes specifically expressed in lymphocytes; (ii) congenital ichthyosis related to mutations in genes specifically expressed in keratinocytes such as LIPN encoding epidermal lipase N (Israeli et al 2011) and PNPLA1 encoding a PNPLA protein involved in glycerophospholipid synthesis (Grall et al 2012) ; (iii) retinal dystrophies; or (iv) renal presentations. It must be stressed that many apparently well clinically defined syndromes are not distinct entities, but rather clusters on a continuous spectrum like for the PNPLA6-associated diseases, ranging from Boucher-Neuhauser syndrome, Gordon Holmes syndrome, spastic ataxia, and pure HSP. Similarly, LCA, EORD and RP may be considered as a continuum spectrum of retinal dystrophies. Likewise, mutations in ABCA4 result in a spectrum of related retinal dystrophies including some forms of Stargardt disease.
Awaiting a more comprehensive overview of this very complex part of cellular metabolism, a clinical approach based on the preponderant presenting symptoms remains therefore the only available one at bedside. The careful grouping of patients in well-defined clinical entities may provide algorithms for orientating metabolic (e.g., lipidomic approaches) and genetic (e.g., exome sequencing) investigations. Of note, these complex molecules synthesis defects are at the crossroad of classical IEM due to an enzymatic block on a catabolic pathway and IEM affecting the synthesis and stability of structural molecules. The concept of complex molecules synthesis defects also opens the window to promising therapeutic trials for example by providing the distal missing compound as has been successfully done in cerebrotendinous xanthomatosis (Berginer et al 1984) , coenzyme Q synthesis defects (Salviati this issue), serine synthesis defects (Méneret et al 2012) , and serine metabolism defects involved in de novo biosynthesis of glycosphingolipids (Garofalo et al 2011) . 
